Genfit (NASDAQ:GNFT) Stock Price Down 2% – What’s Next?

Genfit S.A. (NASDAQ:GNFT) shares were down 2% during mid-day trading on Friday . The stock traded as low as $3.45 and last traded at $3.47. Approximately 7,808 shares traded hands during trading, a decline of 7% from the average daily volume of 8,393 shares. The stock had previously closed at $3.54.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $13.00 target price on shares of Genfit in a research note on Friday, February 7th.

Genfit Stock Down 2.0 %

The stock has a 50-day moving average price of $3.74 and a 200 day moving average price of $4.40. The company has a debt-to-equity ratio of 0.61, a current ratio of 3.74 and a quick ratio of 3.74.

Institutional Trading of Genfit

An institutional investor recently bought a new position in Genfit stock. Millennium Management LLC bought a new stake in Genfit S.A. (NASDAQ:GNFT) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 166,375 shares of the company’s stock, valued at approximately $611,000. Millennium Management LLC owned 0.33% of Genfit as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 2.24% of the company’s stock.

Genfit Company Profile

Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.